US Bio Rakete !

NEW YORK, Oct. 26, 2011  /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a  biopharmaceutical company engaged in the discovery and development of  disease-modifying therapeutic agents for the treatment of Alzheimer's  and other neurological diseases announces today the commencement of the  initial development of its new CONJUMAB-A platform technology for a  novel class of therapeutics for treatment of Alzheimer's disease and  other proteinopathies based on antibody-drug conjugates (ADCs). Dr. Daniel G. Chain, the Company's Chairman and CEO and inventor of the CONJUMAB-A technology, will provide a brief  description of the CONJUMAB-A technology during his presentation at  BioInvestor Forum 2011 and in a video interview at the World ADC Summit,  both taking place in San Francisco this week.

The new ADC- based technology has the potential  to improve on current methods of passive immunotherapy by increasing  clearance of amyloid proteins while delivering potent cytoprotective  molecules to sites of damage in the brain and other organs. CONJUMAB-A  is designed to reduce inflammation caused by amyloidosis while avoiding  vasogenic edema, a side effect of plaque dissolution that occurs in some  patients.  The company's lead CONJUMAB-A candidate is IN-N01-OX2, a  non-activating, stabilized IgG4 humanized antibody specific for beta  amyloid protein conjugated to melatonin, which is a naturally occurring  molecule with potent anti-oxidant and anti-fibrillogenic properties.

"We  believe this exciting new approach may herald a new generation of  promising drug candidates for the treatment of currently untreatable  life-threatening diseases. CONJUMAB-A capitalizes on the tremendous  advances already made in the area of ADCs for cancer which have  generated a plethora of advanced enabling drug conjugation technologies  and also uses independent approaches," said Daniel Chain,  Ph.D., Chairman and CEO of Intellect Neurosciences and inventor of the  CONJUMAB-A technology. "While CONJUMAB-A is still at the earliest stage  of development and requires substantial work before new drug candidates  can be tested in human clinical trials, we are very optimistic regarding  its potential, and look forward to reporting our progress as soon as  possible."

Intellect's new platform may also have applications for  in vivo imaging of amyloid, which may be useful for diagnosis of  disease and monitoring of drug effectiveness. The Company has applied  for a patent for its CONJUMAB-A technology. Intellect has the  exclusively license to certain patents granted by the USPTO to NYU  School of Medicine and the University of South Alabama Research  Foundation specifically covering the use of melatonin for the treatment  of Alzheimer's disease and other types of amyloidosis. The CONJUMAB-A  platform is applicable to a broad range of diseases including,  Alzheimer's, Parkinson's, Huntington's,  Age-Related Macular Degeneration, Glaucoma, Cerebral Angiopathy,  Frontotemporal Dementia, Progressive Supranuclear Palsy, Pick's disease,  Cortical Basal Degeneration and Peripheral Amyloidosis.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative  approaches aimed at arresting or preventing Alzheimer's disease, and  other neurodegenerative diseases especially focused on proteinopathies.  Intellect's pipeline includes small neuroprotective molecules and  neoepitope-based immunotherapy approaches including monoclonal  antibodies and vaccines targeting beta amyloid and abnormal tau  proteins. Previously, Intellect Neurosciences out-licensed late-stage  antibody products based on the company's ANTISENILIN® Alzheimer's beta  amyloid monoclonal antibody technology to several major pharmaceutical  companies. In addition, the company recently licensed OX1 a small  molecule antioxidant to ViroPharma Incorporated for Friedreich's Ataxia  and other neurodegenerative diseases. Currently, the company is focused  on developing next generation antibody therapeutics. Its most advanced  internal candidate is IN-N01-OX2, a humanized monoclonal antibody drug  conjugate that has potential applications to treat Alzheimer's disease,  Early-Onset Familial Alzheimer's disease, cerebral angiopathy,  age-related macular degeneration, glaucoma and traumatic brain injury.  In addition, IN-N01-OX2 has potential applications for in vivo imaging  of beta amyloid in the brain. The company's RECALL-VAX technology is a  proprietary Alzheimer's vaccine with therapeutic and prophylactic  potential.

Safe Harbor Statement Regarding Forward-Looking Statements:

The  statements in this release and oral statements made by representatives  of Intellect relating to matters that are not historical facts  (including, without limitation, those regarding future performance or  financial results, the timing or potential outcomes of research  collaborations or clinical trials, any market  that might develop for any of Intellect's product candidates and the  sufficiency of Intellect's cash and other capital resources) are  forward-looking statements that involve risks and uncertainties,  including, but not limited to, the likelihood that actual performance or  results could materially differ, that future research will prove  successful, the likelihood that any product in the research pipeline  will receive regulatory approval in the United States  or abroad, or Intellect's ability to fund such efforts with or without  partners. Intellect undertakes no obligation to update any of these  statements. Readers are cautioned not to place undue reliance on these  forward-looking statements, which speak only as to the date hereof.  Accordingly, any forward-looking statements should be read in  conjunction with the additional risks and uncertainties detailed in  Intellect's filings with the Securities and Exchange Commission,  including those factors discussed under the caption "Risk Factors" in  Intellect's Annual Report on Form 10-K (file no. 333-128226), filed on October 13, 2011.

Contact:
Jules Abraham
JQA Partners, LLC
jabraham@jqapartners.com
917-885-7378

SOURCE  Intellect Neurosciences, Inc.